Tollys
Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor.
Total raised
€2.3M
€2,300,000
Funding rounds
1
Investors
0
distinct backers
Active since
2020-05
latest 2020-05
Funding by year
EUR raised per yearSignals
Medium confidenceRaise-next likelihood18
base rate 44% for Series A
- ▼ Dormant (no round in 3+ cohort gaps)
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-05-26 | Series A | €2.3M | — | View deal → |
Related news
Similar companies
same sector or country- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Mistral AI€3.5BFrance · AI
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- ContentSquare€1.3BFrance · Software